Interleukin 1 Receptor Antagonist Protein: all 169 studies that test it
Page 2 of 2. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.
- Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell LymphomaTerminatedNCT04205838Phase 2
- A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell TherapyActive, not recruitingNCT04148430Phase 2
- IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous DiseaseCompletedNCT04136028Early Phase 1
- Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled TrialCompletedNCT04099901Phase 2
- Anakinra as a Rescue Treatment for Allergic InflammationWithdrawnNCT04035109Phase 1/2
- Open-label Study of Anakinra in MPS IIICompletedNCT04018755Phase 1/2
- Pilot Study of the IL-1 Antagonist Anakinra for the Treatment of Endometriosis Related SymptomsStatus unknownNCT03991520Early Phase 1
- A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CFTerminatedNCT03925194Phase 2
- BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral HaemorrhageCompletedNCT03737344Phase 2
- Personalized Therapies in Inflammatory Complex DiseaseCompletedNCT03651518Phase 2
- Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary SyndromeCompletedNCT03578497Phase 2
- Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway InflammationWithdrawnNCT03513471Phase 1/2
- Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway InflammationWithdrawnNCT03513458Phase 1/2
- Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult SubjectsStatus unknownNCT03383276Phase 1
- A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and SepsisCompletedNCT03332225Phase 2
- SC IL-1Ra in SAH - Phase III Trial (SCIL)Active, not recruitingNCT03249207Phase 3
- Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCTCompletedNCT03233776Phase 2
- Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-StudyCompletedNCT03200782Not applicable
- Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney DiseaseWithdrawnNCT03062176Phase 2
- Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial HypertensionCompletedNCT03057028Phase 1
- Anakinra Versus Placebo for the Treatment of Acute MyocarditISCompletedNCT03018834Phase 2/3
- IL-1ra Dose-range Study for Moderate-to-severe TBI PatientsStatus unknownNCT02997371Phase 2
- Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory UveitisCompletedNCT02929251Phase 2
- Role of Interleukin (IL)-1 in Postprandial Fatigue - The Chäschüechli 2 StudyCompletedNCT02916355Not applicable
- Giant Cell Arteritis and Anakinra TrialTerminatedNCT02902731Phase 3
- Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OACompletedNCT02790723Phase 1
- Treatment of Macrophage Activation Syndrome (MAS) With AnakinraTerminatedNCT02780583Phase 1
- Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic SyndromeCompletedNCT02672592Phase 3
- Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic CancerCompletedNCT02550327Early Phase 1
- Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 InfectionTerminatedNCT02527460Phase 1
- Anakinra and Kawasaki DiseaseCompletedNCT02390596Phase 2
- IL-1RA, Acute Exercise, and Beta-cell FunctionWithdrawnNCT02310009Not applicable
- Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II StudyTerminatedNCT02263638Phase 2
- Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and DiabetesTerminatedNCT02236481Phase 4
- Effects of IL-1 Beta on the HPA-axis in Obese PersonsCompletedNCT02227420Phase 3
- AnakInRa for Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP)CompletedNCT02219828Phase 4
- Cytokine Inhibition in Chronic Fatigue Syndrome PatientsCompletedNCT02108210Phase 2/3
- Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal CancerCompletedNCT02090101Phase 2
- A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard ChemotherapyCompletedNCT02021422Phase 1
- Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee ArhroscopyWithdrawnNCT01997138Phase 4
- Role of Interleukin-1 in Postprandial Fatigue - The Cheesecake StudyCompletedNCT01810549Phase 1
- Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During ExerciseCompletedNCT01771445Not applicable
- Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean FeverCompletedNCT01705756Phase 3
- Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced CancersCompletedNCT01624766Phase 1
- Effects of Interleukin-1 Inhibition on Vascular and Left Ventricular Function in Rheumatoid Arthritis Patients With Coronary Artery DiseaseCompletedNCT01566201Not applicable
- Anakinra in Hidradenitis SuppurativaCompletedNCT01558375Phase 2
- Anti-IL-1 Treatment in Children Diabetic Keto-Acidosis (DKA) at Diagnosis of Type 1 DiabetesWithdrawnNCT01477476Phase 2
- Effect of Interleukin-1 Receptor Antagonist on Inhalation of 20,000 EU Clinical Ctr Reference Endotoxin in Normal VolunteersCompletedNCT01369017Phase 1
- Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes MellitusStatus unknownNCT01285245Phase 2
- The Effect of Anakinra on Insulin SecretionStatus unknownNCT01285232Not applicable
- Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral SclerosisCompletedNCT01277315Phase 2
- Anakinra in MyositisCompletedNCT01165008Phase 2/3
- A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic DermatitisTerminatedNCT01122914Phase 1
- Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized StudyCompletedNCT01033656Phase 2
- Interleukin-1 Receptor Antagonist and Insulin SensitivityStatus unknownNCT00928876Phase 2
- Anti-Interleukin-1 in Diabetes ActionCompletedNCT00711503Phase 2/3
- Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens SyndromeCompletedNCT00683345Phase 2
- Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITISCompletedNCT00339157Phase 2/3
- Study to Prevent Cartilage Damage Following Acute Knee Injury.CompletedNCT00332254Phase 1/2
- Treatment of Patients With Type 2 Diabetes With an Interleukin-1 AntagonistCompletedNCT00303394Phase 2
- The Use of Kineret (Anakinra) in the Treatment of Familial Cold UrticariaCompletedNCT00214851Phase 1
- Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported QuestionnaireCompletedNCT00121043Phase 4
- Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)CompletedNCT00117091Phase 3
- Evaluating the Effect of Anakinra (r-metHuIL-1ra) on Vaccine AntibodyResponse in Subjects With Rheumatoid Arthritis (RA)CompletedNCT00111410Phase 4
- Treatment for Patients With Osteoarthritis (OA) of the KneeCompletedNCT00110916Phase 2
- Anakinra in Treating Patients With Metastatic Cancer Expressing the Interleukin-1 GeneCompletedNCT00072111Phase 1
- A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving MethotrexateCompletedNCT00038298Phase 2
- Evaluation of the Efficacy of Combination Treatment With Anakinra and Pegsunercept in Improving Rheumatoid ArthritisCompletedNCT00037700Phase 2
- Juvenile Rheumatoid ArthritisCompletedNCT00037648Phase 2